Painbloc24
NDC 71226-001
Product Information
Painbloc24 is a OTC MONOGRAPH NOT FINAL-approved product labeled by Vizuri Health Sciences Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a product. This product entry covers the primary NDC 71226-001 and 4 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 71226-001?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CAPSAICIN (UNII: S07O44R1ZM)
- CAPSAICIN (UNII: S07O44R1ZM) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ALCOHOL (UNII: 3K9958V90M)
- DIETHYLENE GLYCOL MONOETHYL ETHER (UNII: A1A1I8X02B)
- HYALURONATE SODIUM (UNII: YSE9PPT4TH)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- WATER (UNII: 059QF0KO0R)
- PRAMOXINE HYDROCHLORIDE (UNII: 88AYB867L5)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1874747 - capsaicin 0.25 % Topical Solution
- RxCUI: 1874747 - capsaicin 2.5 MG/ML Topical Solution
* Please review the full disclaimer at the bottom of this page.
Patient Education
Capsaicin Topical
Topical capsaicin is used to relieve minor pain in muscles and joints caused by arthritis, backaches, muscle strains, bruises, cramps, and sprains. Capsaicin is a substance that is found in chili peppers. It works by affecting nerve cells in the skin that are associated with pain, which results in decreased activity of these nerve cells and a reduced sense of pain.
[Learn More]
* Please review the full disclaimer at the bottom of this page.